Assessment of endothelial dysfunction in spondyloarthritis

Background: Endothelial dysfunction is the earliest step in the pathogenesis of atherosclerosis, preceding structural vascular alterations. Few studies have focused on the endothelial dysfunction in spondyloarthritis. Objectives: The aim of our study was to assess endothelial dysfunction using Flow-Mediated dilatation (FMD) in patients with spondyloarthritis. Methods: Forty-seven consecutive patients meeting ASAS 2009 criteria for spondyloarthritis and 47 matched healthy subjects were included in the study. Subjects with traditional cardiovascular risk factors were excluded. Sociodemographic, clinical, biological and radiological features related to the disease as well as therapeutics were recorded. FMD was assessed ultrasonographically according to guidelines of American college of cardiology (ACC) (1). Results: Spondyloarthritis group included 47 patients with a sex ratio of 2.35 and a median age of 36 years (IQR: 28-46). Median body mass index (BMI) was 24.5 kg/m2 (IQR 25-75%: 20.7-26.8) with no significant difference compared with the control group (p=0.238). Physical examination showed normal values of blood pressure (BP) with a median systolic BP of 121 mmHg (IQR 25-75%: 110-130) and a median diastolic BP of 71 mmHg (IQR 25-75%: 67-78). In laboratory findings, total cholesterol and triglyceride levels were increased in 2 and 3 patients respectively. Median age at onset of SpA was 20 years (IQR 25-75%; 18-32). For disease activity, median CRP level was 6.45 mg (IQR 25-75%: 1.45-19.9) and median ASDAS-CRP and BASDAI were respectively 2.18 (IQR 25-75%: 1.62-2.91) and 2.6 (IQR 25-75%: 1.8-3.8). Median MASES score was 0 (IQR 25-75%; 0-0). Median BASFI and BASMI were 3 (IQR 25-75%; 1.5-5.1) and 1.5 (IQR 25-75%: 0-4). Regarding treatment, 92% of patients were using NSAIDs, csDMARDs (51%) and 38% were on TNF inhibitors. Patients with spondyloarthritis exhibited significantly lower FMD values than healthy age and gender matched controls with a median value of FMD 14.6% (IQR; 9-24) versus 18.8% (IQR; 12.8-23.1%); p=0.008. Conclusion: Our study demonstrates impairment of endothelial function in patients with spondyloarthritis compared with healthy population, confirming the accelerated atherosclerosis in spondyloarthritis. REFERENCES: [1]Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534–47. Disclosure of Interests: None declared Citation: , volume 81, supplement 1, year 2022, page 1551Session: Spondyloarthritis - clinical aspects (other than treatment) (Publication Only)